Previous close | 0.2895 |
Open | 0.2895 |
Bid | 0.0000 x 0 |
Ask | 0.0000 x 0 |
Day's range | 0.2895 - 0.2895 |
52-week range | 0.2860 - 0.7660 |
Volume | |
Avg. volume | 0 |
Market cap | N/A |
Beta (5Y monthly) | N/A |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
PRESS RELEASE - 22 November 2023, 10:00 CET BIOCARTIS HOLDINGS INC. RECAPITALIZATION COMPLETED AND PRODUCT PORTFOLIO EXPANSION The recapitalization of Biocartis was completed last week, strengthening the balance sheet with a new investment of €40 million and a €132 million conversion of debt to equity.Product portfolio expansion with the launch of three breast cancer products: the Idylla™ PIK3CA-AKT1 Mutation Assay and, in collaboration with our partner APIS, the APIS Breast Cancer Subtyping Kit
PRESS RELEASE - 13 November 2023, 07:00 CET Biocartis Hosts Corporate Workshop and Announces Seven Idylla™ Abstracts to be Presented at AMP 2023 Annual Meeting Mechelen, Belgium and Itasca (IL), United States, 13 November 2023 – Biocartis, an innovative molecular diagnostics company, announces today that it will host a free corporate workshop at the Annual Meeting of the ‘Association for Molecular Pathology’ (AMP), a leading molecular diagnostics conference, taking place between 14-18 November 2
PRESS RELEASE REGULATED INFORMATION 31 October 2023, 15:30 CET ANNOUNCEMENT REGARDING ENFORCEMENT BY SECURED CREDITORS The Company’s Secured Creditors have enforced their security over the shares of the Biocartis operating subsidiaries Enforcement not expected to impact Biocartis's customers, suppliers, partners or employees Mechelen, Belgium, 31 October 2023 – Biocartis Group NV (the “Company”) (Euronext Brussels: BCART) announces that it has been informed by its Secured Creditors (as defined b